Verena Vondey

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
To elucidate their mechanism of action, inhibitors of Bruton tyrosine kinase (BTK) and resistant BTK mutants were employed to dissect target-dependent cellular functions. BTK-C481S and -T474I, expressed in Ramos and NALM-6 cells, maintained BTK auto-phosphorylation under treatment with ibrutinib or dasatinib, respectively, which showed only modest(More)
Chronic lymphocytic leukemia (CLL) represents the most prevalent adult leukemia and is characterized by the accumulation of long-lived B lymphocytes. Despite significant advances in its therapy especially during the last two decades, the disease still remains incurable and new treatment options need to be developed. Among targeted approaches, immunotherapy(More)
Pharmacological inhibition of phosphatiylinositide-3-kinase (PI3K)-mediated signaling holds great promise for treating chronic lymphocytic leukemia (CLL). Therefore we assessed three structurally related PI3K inhibitors targeting the PI3K-δ isoform for their ability to inhibit the survival of freshly isolated CLL cells. The purely PI3K-δ-selective inhibitor(More)
  • 1